GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma

This article was originally published here

Trelegy Ellipta, which is a once-daily, single-inhaler triple therapy, was approved by the US Food and Drug Administration (FDA) in late 2017 for the long-term, once-daily maintenance treatment

The post GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply